Unresectable recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) has a very poor prognosis. Soluble immune checkpoints (sICs) are circulating proteins that result from the alternative splicing of membrane proteins and can modulate the immune response to cancer cells. The aim of our pilot study was to determine the possible role of a comprehensive evaluation of sICs in the classification of prognosis and response to treatment in patients with advanced disease. We evaluated several sICs (CD137, CTLA-4, PD-1, PD-L1, PD-L2, TIM3, LAG3, GITR, HVEM, BTLA, IDO, CD80, CD27, and CD28) from peripheral blood at baseline and investigated the association with clinical characteristics and outcomes. A high baseline soluble LAG3 (sLAG3 > 377 pg/mL) resulted in an association with poor PFS and OS (p = 0.047 and p = 0.003, respectively). Moreover, sLAG3 emerged as an independent prognostic factor using an MVA (p = 0.005). The evaluation of sICs, in particular sLAG3, may be relevant for identifying patients with worse prognoses, or resistance to treatments, and may lead to the development of novel targeted strategies

The role of soluble LAG3 and soluble immune checkpoints profile in advanced head and neck cancer: a pilot study / Botticelli, Andrea; Zizzari, Ilaria Grazia; Scagnoli, Simone; Pomati, Giulia; Strigari, Lidia; Cirillo, Alessio; Cerbelli, Bruna; Di Filippo, Alessandra; Napoletano, Chiara; Scirocchi, Fabio; Rughetti, Aurelia; Nuti, Marianna; Mezi, Silvia; Marchetti, Paolo. - In: JOURNAL OF PERSONALIZED MEDICINE. - ISSN 2075-4426. - 11:7(2021). [10.3390/jpm11070651]

The role of soluble LAG3 and soluble immune checkpoints profile in advanced head and neck cancer: a pilot study

Andrea Botticelli
Co-primo
;
Ilaria Grazia Zizzari
Co-primo
;
Simone Scagnoli
;
Giulia Pomati;Alessio Cirillo;Bruna Cerbelli;Alessandra Di Filippo;Chiara Napoletano;Fabio Scirocchi;Aurelia Rughetti;Marianna Nuti;Silvia Mezi
Penultimo
;
Paolo Marchetti
Ultimo
2021

Abstract

Unresectable recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) has a very poor prognosis. Soluble immune checkpoints (sICs) are circulating proteins that result from the alternative splicing of membrane proteins and can modulate the immune response to cancer cells. The aim of our pilot study was to determine the possible role of a comprehensive evaluation of sICs in the classification of prognosis and response to treatment in patients with advanced disease. We evaluated several sICs (CD137, CTLA-4, PD-1, PD-L1, PD-L2, TIM3, LAG3, GITR, HVEM, BTLA, IDO, CD80, CD27, and CD28) from peripheral blood at baseline and investigated the association with clinical characteristics and outcomes. A high baseline soluble LAG3 (sLAG3 > 377 pg/mL) resulted in an association with poor PFS and OS (p = 0.047 and p = 0.003, respectively). Moreover, sLAG3 emerged as an independent prognostic factor using an MVA (p = 0.005). The evaluation of sICs, in particular sLAG3, may be relevant for identifying patients with worse prognoses, or resistance to treatments, and may lead to the development of novel targeted strategies
File allegati a questo prodotto
File Dimensione Formato  
Botticelli_The Role of_2021.pdf

accesso aperto

Note: https://www.mdpi.com/2075-4426/11/7/651
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.36 MB
Formato Adobe PDF
1.36 MB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/1562092
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact